XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock Options and Restricted Stock Units (Tables)
3 Months Ended
Mar. 31, 2024
Stock Options and Restricted Stock Units  
Schedule of stock-based compensation expense

For the Three Months Ended

March 31, 

    

2024

    

2023

Direct operating costs

$

84

$

63

Selling and administrative expenses

 

950

 

899

Total stock-based compensation

$

1,034

$

962

Schedule of weighted-average fair value of the options granted, and weighted-average assumptions

For the Three Months Ended March 31, 

    

2024

    

2023

Weighted average fair value of options granted

$

-

$

1.79

Risk-free interest rate

-

3.88

%

Expected term (years)

-

3.0

Expected volatility factor

-

79.95

%

Expected dividends

-

-

Equity Plans  
Stock Options and Restricted Stock Units  
Schedule of stock option activity

 

 

 

Weighted-Average

 

Number of

 

Weighted - Average

 

Remaining Contractual

Aggregate

    

Options

    

Exercise Price

    

Term (years)

    

Intrinsic Value

Outstanding at January 1, 2024

 

5,339,162

$

3.22

 

6.38

 

$

28,640,009

Granted

 

-

 

-

 

-

 

-

Exercised

 

-

 

-

 

-

 

-

Forfeited/Expired

 

(2,334)

 

6.96

 

-

 

-

Outstanding at March 31, 2024

 

5,336,828

$

3.21

 

6.13

$

18,364,840

 

 

 

 

Exercisable at March 31, 2024

 

3,552,030

$

2.28

5.22

$

15,528,015

 

 

 

 

Vested and Expected to Vest at March 31, 2024

 

5,336,828

$

3.21

 

6.13

$

18,364,840

    

    

    

Weighted-Average 

    

Number of 

Weighted - Average 

Remaining Contractual 

Aggregate 

Options

Exercise Price

Term (years)

Intrinsic Value

Outstanding at January 1, 2023

6,690,490

$

3.09

7.19

$

5,989,709

Granted*

 

25,000

 

3.31

 

-

 

-

Exercised

 

(148,167)

 

2.31

 

-

 

-

Forfeited/Expired

 

(64,666)

 

6.96

 

-

 

-

Outstanding at March 31, 2023

 

6,502,657

$

3.07

 

6.94

$

35,414,546

Exercisable at March 31, 2023

 

4,041,942

$

2.03

 

5.87

$

26,301,295

Vested and Expected to Vest at March 31, 2023

 

6,502,657

$

3.07

 

6.94

$

35,414,546

*Includes 25,000 stock granted to a non-employee member of the Company’s advisory board.

Weighted-Average

Number of

Weighted - Average

Remaining Contractual

Aggregate

    

Options

    

Exercise Price

    

Term (years)

    

Intrinsic Value

Outstanding at January 1, 2024

 

923,571

$

3.41

 

8.76

 

$

4,786,252

Granted

 

-

 

-

 

-

 

-

Exercised

 

-

 

-

 

-

 

-

Forfeited/Expired

 

(5,334)

 

3.41

 

-

 

-

Outstanding at March 31, 2024

 

918,237

$

3.41

 

8.52

$

2,946,506

Exercisable at March 31, 2024

 

386,209

$

3.34

 

8.49

$

1,258,907

Vested and Expected to Vest at March 31, 2024

 

918,237

$

3.41

 

8.52

$

2,946,506

    

    

    

Weighted-Average

    

Number of 

Weighted - Average

Remaining Contractual

Aggregate

Options

Exercise Price

Term (years)

Intrinsic Value

Outstanding at January 1, 2023

 

1,027,500

$

3.46

 

9.75

 

$

-

Granted

 

-

 

-

 

-

 

-

Exercised

 

-

 

-

 

-

 

-

Forfeited/Expired

 

(33,500)

 

3.41

 

-

 

-

Outstanding at March 31, 2023

 

994,000

$

3.46

 

9.51

$

5,051,370

Exercisable at March 31, 2023

 

31,250

$

5.20

 

9.29

$

104,500

Vested and Expected to Vest at March 31, 2023

 

994,000

$

3.46

 

9.51

$

5,051,370

Restricted Stock Units  
Stock Options and Restricted Stock Units  
Summary of restricted stock under the company's plan

Number of 

 

Weighted-Average

Restricted Stock

Grant Date

    

Units

    

 Fair Value

Unvested at January 1, 2024

749,756

$

5.77

Granted

 

-

 

-

Vested

 

-

 

-

Forfeited/Expired

 

(995)

 

8.29

Unvested at March 31, 2024

 

748,761

$

5.78

    

Number of

    

Weighted-Average

Restricted Stock

Grant Date

Units

Fair Value

Unvested at January 1, 2023

 

700,000

$

5.59

Granted

 

-

 

-

Vested

 

-

 

-

Forfeited/Expired

 

-

 

-

Unvested at March 31, 2023

 

700,000

$

5.59